???pagination.result.count???
???pagination.result.page???
1
ADAM 13: a novel ADAM expressed in somitic mesoderm and neural crest cells during Xenopus laevis development. , Alfandari D , Alfandari D , Wolfsberg TG, White JM, DeSimone DW ., Dev Biol. February 15, 1997; 182 (2): 314-30.
Identification and characterization of novel mouse and human ADAM33s with potential metalloprotease activity. , Yoshinaka T, Nishii K, Yamada K, Sawada H, Nishiwaki E, Smith K , Yoshino K, Ishiguro H, Higashiyama S., Gene. January 9, 2002; 282 (1-2): 227-36.
ADAM13 disintegrin and cysteine-rich domains bind to the second heparin-binding domain of fibronectin. , Gaultier A , Cousin H , Darribère T , Alfandari D , Alfandari D ., J Biol Chem. June 28, 2002; 277 (26): 23336-44.
Conservation and divergence of ADAM family proteins in the Xenopus genome. , Wei S , Whittaker CA, Xu G, Bridges LC, Shah A, White JM, Desimone DW ., BMC Evol Biol. July 14, 2010; 10 211.
Phylogenetic and molecular evolution of the ADAM (A Disintegrin And Metalloprotease) gene family from Xenopus tropicalis, to Mus musculus, Rattus norvegicus, and Homo sapiens. , Long J, Li M, Ren Q, Zhang C, Fan J, Duan Y, Chen J , Li B, Deng L., Gene. October 1, 2012; 507 (1): 36-43.
Hmga2 is required for neural crest cell specification in Xenopus laevis. , Macrì S, Simula L, Pellarin I, Pegoraro S, Onorati M, Sgarra R, Manfioletti G, Vignali R ., Dev Biol. March 1, 2016; 411 (1): 25-37.
Xenopus ADAM19 regulates Wnt signaling and neural crest specification by stabilizing ADAM13. , Li J, Perfetto M, Neuner R, Bahudhanapati H, Christian L, Mathavan K, Bridges LC, Alfandari D , Alfandari D , Wei S ., Development. April 4, 2018; 145 (7):
Maximizing CRISPR/Cas9 phenotype penetrance applying predictive modeling of editing outcomes in Xenopus and zebrafish embryos. , Naert T, Tulkens D, Edwards NA , Carron M, Shaidani NI , Wlizla M , Boel A, Demuynck S, Horb ME , Coucke P, Willaert A, Zorn AM , Vleminckx K , Vleminckx K ., Sci Rep. September 4, 2020; 10 (1): 14662.
CRISPR-SID: Identifying EZH2 as a druggable target for desmoid tumors via in vivo dependency mapping. , Naert T, Tulkens D, Van Nieuwenhuysen T, Przybyl J, Demuynck S, van de Rijn M, Al-Jazrawe M, Alman BA, Coucke PJ, De Leeneer K, Vanhove C, Savvides SN, Creytens D, Vleminckx K , Vleminckx K ., Proc Natl Acad Sci U S A. November 23, 2021; 118 (47):